In:
European Journal of Immunology, Wiley, Vol. 51, No. 3 ( 2021-03), p. 662-671
Abstract:
The IL‐1 family member IL‐38 (IL1F10) suppresses inflammatory and autoimmune conditions. Here, we report that plasma concentrations of IL‐38 in 288 healthy Europeans correlate positively with circulating memory B cells and plasmablasts. IL‐38 correlated negatively with age ( p = 0.02) and was stable in 48 subjects for 1 year. In comparison with primary keratinocytes, IL1F10 expression in CD19 + B cells from PBMC was lower, whereas cell‐associated IL‐38 expression was comparable. In vitro, IL‐38 is released from CD19 + B cells after stimulation with rituximab. Intravenous LPS in humans failed to induce circulating IL‐38, compared to 100‐fold induction of IL‐6 and IL‐1 receptor antagonist. In a cohort of 296 subjects with body mass index 〉 27 at high risk for cardiovascular disease, IL‐38 plasma concentrations were significantly lower than in healthy subjects ( p 〈 0.0001), and lowest in those with metabolic syndrome ( p 〈 0.05). IL‐38 also correlated inversely with high sensitivity C‐reactive protein ( p 〈 0.01), IL‐6, IL‐1Ra, and leptin ( p 〈 0.05). We conclude that a relative deficiency of the B cell product IL‐38 is associated with increased systemic inflammation in aging, cardiovascular and metabolic disease, and is consistent with IL‐38 as an anti‐inflammatory cytokine.
Type of Medium:
Online Resource
ISSN:
0014-2980
,
1521-4141
DOI:
10.1002/eji.201948390
Language:
English
Publisher:
Wiley
Publication Date:
2021
detail.hit.zdb_id:
120108-6
detail.hit.zdb_id:
1491907-2